276 related articles for article (PubMed ID: 17000691)
1. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.
Foster PA; Newman SP; Chander SK; Stengel C; Jhalli R; Woo LL; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2006 Sep; 12(18):5543-9. PubMed ID: 17000691
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.
Foster PA; Chander SK; Parsons MF; Newman SP; Woo LW; Potter BV; Reed MJ; Purohit A
Breast Cancer Res Treat; 2008 Sep; 111(1):129-38. PubMed ID: 17914670
[TBL] [Abstract][Full Text] [Related]
3. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
[TBL] [Abstract][Full Text] [Related]
4. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy.
Day JM; Purohit A; Tutill HJ; Foster PA; Woo LW; Potter BV; Reed MJ
Ann N Y Acad Sci; 2009 Feb; 1155():80-7. PubMed ID: 19250195
[TBL] [Abstract][Full Text] [Related]
5. Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Stanway SJ; Delavault P; Purohit A; Woo LW; Thurieau C; Potter BV; Reed MJ
Oncologist; 2007 Apr; 12(4):370-4. PubMed ID: 17470679
[TBL] [Abstract][Full Text] [Related]
6. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.
Foster PA; Woo LW; Potter BV; Reed MJ; Purohit A
Endocrinology; 2008 Aug; 149(8):4035-42. PubMed ID: 18450955
[TBL] [Abstract][Full Text] [Related]
7. Development of novel steroid sulfatase inhibitors; II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats.
Saito T; Kinoshita S; Fujii T; Bandoh K; Fuse S; Yamauchi Y; Koizumi N; Horiuchi T
J Steroid Biochem Mol Biol; 2004 Feb; 88(2):167-73. PubMed ID: 15084348
[TBL] [Abstract][Full Text] [Related]
8. Steroid metabolism in breast cancer.
Foster PA
Minerva Endocrinol; 2008 Mar; 33(1):27-37. PubMed ID: 18277377
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy.
Purohit A; Chander SK; Woo LW; Parsons MF; Jhalli R; Potter BV; Reed MJ
Anticancer Res; 2008; 28(3A):1517-23. PubMed ID: 18630506
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
Stanway SJ; Purohit A; Woo LW; Sufi S; Vigushin D; Ward R; Wilson RH; Stanczyk FZ; Dobbs N; Kulinskaya E; Elliott M; Potter BV; Reed MJ; Coombes RC
Clin Cancer Res; 2006 Mar; 12(5):1585-92. PubMed ID: 16533785
[TBL] [Abstract][Full Text] [Related]
11. 6-[2-(adamantylidene)-hydroxybenzoxazole]-O-sulfamate, a steroid sulfatase inhibitor for the treatment of androgen- and estrogen-dependent diseases.
Billich A; Meingassner JG; Nussbaumer P; Desrayaud S; Lam C; Winiski A; Schreiner E
J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):29-37. PubMed ID: 15544928
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of hormone therapy on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro.
Stute P; Götte M; Kiesel L
Breast Cancer Res Treat; 2008 Apr; 108(3):363-74. PubMed ID: 17546497
[TBL] [Abstract][Full Text] [Related]
13. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.
Utsumi T; Leese MP; Chander SK; Gaukroger K; Purohit A; Newman SP; Potter BV; Reed MJ
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):219-27. PubMed ID: 15862969
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor.
Purohit A; Woo LW; Singh A; Winterborn CJ; Potter BV; Reed MJ
Cancer Res; 1996 Nov; 56(21):4950-5. PubMed ID: 8895749
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: x-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene.
Hejaz HA; Purohit A; Mahon MF; Reed MJ; Potter BV
J Med Chem; 1999 Aug; 42(16):3188-92. PubMed ID: 10447965
[TBL] [Abstract][Full Text] [Related]
16. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase.
Woo LW; Howarth NM; Purohit A; Hejaz HA; Reed MJ; Potter BV
J Med Chem; 1998 Mar; 41(7):1068-83. PubMed ID: 9544207
[TBL] [Abstract][Full Text] [Related]
17. A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models.
Ishida H; Nakata T; Suzuki M; Shiotsu Y; Tanaka H; Sato N; Terasaki Y; Takebayashi M; Anazawa H; Murakata C; Li PK; Kuwabara T; Akinaga S
Breast Cancer Res Treat; 2007 Dec; 106(2):215-27. PubMed ID: 17268815
[TBL] [Abstract][Full Text] [Related]
18. Shu-Gan-Liang-Xue Decoction, a Chinese herbal formula, down-regulates the expression of steroid sulfatase genes in human breast carcinoma MCF-7 cells.
Zhang Y; Li PP
J Ethnopharmacol; 2010 Feb; 127(3):620-4. PubMed ID: 20015473
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase.
Hejaz HA; Woo LW; Purohit A; Reed MJ; Potter BV
Bioorg Med Chem; 2004 May; 12(10):2759-72. PubMed ID: 15110857
[TBL] [Abstract][Full Text] [Related]
20. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]